Nucleolar enlargement, nuclear eccentricity and altered cell body immunostaining characteristics of large-sized sensory neurons following treatment of rats with paclitaxel.
Paclitaxel-induced sensory neuropathy is a problematic side-effect of cancer chemotherapy. Previous studies in rodents have shown paclitaxel treatment to have many effects on different parts of the peripheral nervous system, but those responsible for its bothersome clinical side-effects are still unclear. In the current study, we sought to obtain information about the involvement of sensory neurons in paclitaxel neurotoxicity at the level of the dorsal root ganglion. Rats were treated with a clinically relevant dose of paclitaxel (87.5mg/m(2) weekly for a total of nine doses) to induce a sensory neuropathy; then their L5 dorsal root ganglia were studied by morphometry and immunohistochemistry. Paclitaxel treatment was generally well tolerated, and slowed conduction velocity and prolonged conduction latencies in the peripheral sensory nerves without altering conduction in the central or motor pathways of the H-reflex arc. In the L5 dorsal root ganglion, nucleolus size and the number of neurons with eccentric nuclei were increased only in a subpopulation of dorsal root ganglion neurons with cell body cross-sectional areas greater than 1750 microm(2), which made up less than 10% of the total population. Paclitaxel treatment increased immunohistochemical staining for activating transcription factor-3 (ATF-3), c-Jun and neuropeptide Y (NPY) but only in a small percentage of neuronal cell bodies and mainly in those with large cell bodies. In conclusion, we have demonstrated that nucleolar enlargement, nuclear eccentricity, ATF-3, c-Jun and NPY are neuronal markers of paclitaxel-induced sensory neuropathy, however, these axotomy-like cell body reactions are infrequent and occur in mainly large-sized sensory neurons.
Department of Pharmacology and Clinical Pharmacology, The University of Auckland, New Zealand.
S M F
SM
Jamieson
J J
JJ
Liu
B
B
Connor
M
M
Dragunow
M J
MJ
McKeage
D051700:Activating Transcription Factor 3 / Q000032:analysis; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic; D002466:Cell Nucleolus / Q000473:pathology*; D048429:Cell Size; D004195:Disease Models, Animal; D005260:Female; D005727:Ganglia, Spinal / Q000737:chemistry / Q000473:pathology* / Q000503:physiopathology; D006181:H-Reflex; D007150:Immunohistochemistry; D009431:Neural Conduction; D009475:Neurons, Afferent / Q000737:chemistry / Q000473:pathology*; D009478:Neuropeptide Y / Q000032:analysis; D020258:Neurotoxicity Syndromes / Q000209:etiology / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D017239:Paclitaxel; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000378:metabolism / Q000473:pathology* / Q000503:physiopathology; D016755:Proto-Oncogene Proteins c-jun / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time; D015854:Up-Regulation
D051700:Activating Transcription Factor 3; D000972:Antineoplastic Agents, Phytogenic; C497108:Atf3 protein, rat; D009478:Neuropeptide Y; D016755:Proto-Oncogene Proteins c-jun; D017239:Paclitaxel